GlassScriptPhysician profile
Brittany M Hall
NPI 1568759710
$5,760.51
in general payments reported to CMS, 2019-2025
31 companies · $1,412 in 2025
The $1,412 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $883 · 2022: $1,321 · 2023: $988 · 2024: $1,157 · 2025: $1,412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,556.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,607.89 | 2021-2025 | |
| Janssen Biotech, INC. | $685.01 | 2021-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $583.45 | 2021-2025 | Xifaxan, Trulance |
| Celgene Corporation | $495.39 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $431.89 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Madrigal Pharmaceuticals | $186.06 | 2025 | Rezdiffra |
| Ironwood Pharmaceuticals, INC | $183.52 | 2021-2024 | Linzess |
| Gilead Sciences, INC. | $144.83 | 2021-2025 | |
| Redhill Biopharma INC. | $129.42 | 2021-2023 | Talicia |
| Celltrion USA INC. | $127.79 | 2024-2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $113.35 | 2023-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $113.27 | 2024-2025 | Dupixent |
| Pfizer INC. | $107.14 | 2024-2025 | |
| Genzyme Corporation | $101.88 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $90.23 | 2024-2025 | Iqirvo, Bylvay |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $83.43 | 2022-2023 | Terlivaz |
| Braintree Laboratories, INC. | $66.68 | 2021-2024 | Suflave, Sutab |
| Qol Medical, LLC | $64.91 | 2022-2025 | Sucraid |
| Medtronic, INC. | $60.06 | 2024 | Interstim |
| Nestle Healthcare Nutrition INC. | $59.85 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $53.18 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $46.83 | 2021-2024 | Rebyota |
| Pharmacosmos Therapeutics INC. | $42.42 | 2021 | |
| Daiichi Sankyo INC. | $40.51 | 2022 | |
| Novo Nordisk INC | $35.07 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $26.95 | 2025 | Omvoh |
| Aimmune Therapeutics, INC. | $18.97 | 2025 | Zenpep |
| Amgen INC. | $17.56 | 2023 | Avsola, Amjevita |
| Merck Sharp & Dohme LLC | $15.47 | 2023 | Dificid |
| Evoke Pharma, INC. | $15.40 | 2022 | |
| Alnylam Pharmaceuticals INC. | $12.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.